View in EDS

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Saved in:
Bibliographic Details
Title: Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
Authors: Munoz-Couselo E; Vall d'Hebron University Hospital, VHIO, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Soria Rivas A; Department of Medical Oncology, University Hospital Ramón y Cajal, Madrid, Spain., Sandhu S; Department of Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia., Sanmamed MF; Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Spreafico A; Division of Medical Oncology, Princess Margaret Cancer Centre University Health Network, Toronto, Canada., Buchbinder E; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Sznol M; Yale University School of Medicine, New Haven, Connecticut., Prenen H; Antwerp University Hospital, Edegem, Belgium., Fedenko A; P.A. Gertsen Moscow Oncology Research Institute, Moscow, Russia., Milhem M; University of Iowa, Iowa City, Iowa., Arance Fernandez AM; Department of Oncology, Hospital Clínic of Barcelona and IDIBAPS, Barcelona, Spain., Grob JJ; APHM and Aix-Marseille University, Marseille, France., Demidov L; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia., Robert C; Institut Gustave Roussy and Paris Saclay University, Villejuif, France., Habigt C; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich, Munich, Germany., Evers S; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Sleiman N; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Dejardin D; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Ardeshir C; F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom., Martin N; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland., Boetsch C; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Charo J; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland., Teichgräber V; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Kraxner A; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Keshelava N; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland., Bechter O; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium.
Source: Cancer research communications [Cancer Res Commun] 2025 Feb 01; Vol. 5 (2), pp. 358-368.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39895413
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Munoz-Couselo+E%22">Munoz-Couselo E</searchLink>; Vall d'Hebron University Hospital, VHIO, Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Soria+Rivas+A%22">Soria Rivas A</searchLink>; Department of Medical Oncology, University Hospital Ramón y Cajal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Sandhu+S%22">Sandhu S</searchLink>; Department of Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Long+GV%22">Long GV</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Sanmamed+MF%22">Sanmamed MF</searchLink>; Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Spreafico+A%22">Spreafico A</searchLink>; Division of Medical Oncology, Princess Margaret Cancer Centre University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Buchbinder+E%22">Buchbinder E</searchLink>; Beth Israel Deaconess Medical Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Sznol+M%22">Sznol M</searchLink>; Yale University School of Medicine, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Prenen+H%22">Prenen H</searchLink>; Antwerp University Hospital, Edegem, Belgium.<br /><searchLink fieldCode="AU" term="%22Fedenko+A%22">Fedenko A</searchLink>; P.A. Gertsen Moscow Oncology Research Institute, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Milhem+M%22">Milhem M</searchLink>; University of Iowa, Iowa City, Iowa.<br /><searchLink fieldCode="AU" term="%22Arance+Fernandez+AM%22">Arance Fernandez AM</searchLink>; Department of Oncology, Hospital Clínic of Barcelona and IDIBAPS, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Grob+JJ%22">Grob JJ</searchLink>; APHM and Aix-Marseille University, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Demidov+L%22">Demidov L</searchLink>; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Robert+C%22">Robert C</searchLink>; Institut Gustave Roussy and Paris Saclay University, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Habigt+C%22">Habigt C</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Evers+S%22">Evers S</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Sleiman+N%22">Sleiman N</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Dejardin+D%22">Dejardin D</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ardeshir+C%22">Ardeshir C</searchLink>; F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Martin+N%22">Martin N</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Boetsch+C%22">Boetsch C</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Charo+J%22">Charo J</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Teichgräber+V%22">Teichgräber V</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kraxner+A%22">Kraxner A</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Keshelava+N%22">Keshelava N</searchLink>; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bechter+O%22">Bechter O</searchLink>; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918281580506676%22">Cancer research communications</searchLink> [Cancer Res Commun] 2025 Feb 01; Vol. 5 (2), pp. 358-368.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918281580506676 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2767-9764 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227679764%22">27679764 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Res Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39895413
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/2767-9764.CRC-24-0601
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 358
    Titles:
      – TitleFull: Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Munoz-Couselo E
      – PersonEntity:
          Name:
            NameFull: Soria Rivas A
      – PersonEntity:
          Name:
            NameFull: Sandhu S
      – PersonEntity:
          Name:
            NameFull: Long GV
      – PersonEntity:
          Name:
            NameFull: Sanmamed MF
      – PersonEntity:
          Name:
            NameFull: Spreafico A
      – PersonEntity:
          Name:
            NameFull: Buchbinder E
      – PersonEntity:
          Name:
            NameFull: Sznol M
      – PersonEntity:
          Name:
            NameFull: Prenen H
      – PersonEntity:
          Name:
            NameFull: Fedenko A
      – PersonEntity:
          Name:
            NameFull: Milhem M
      – PersonEntity:
          Name:
            NameFull: Arance Fernandez AM
      – PersonEntity:
          Name:
            NameFull: Grob JJ
      – PersonEntity:
          Name:
            NameFull: Demidov L
      – PersonEntity:
          Name:
            NameFull: Robert C
      – PersonEntity:
          Name:
            NameFull: Habigt C
      – PersonEntity:
          Name:
            NameFull: Evers S
      – PersonEntity:
          Name:
            NameFull: Sleiman N
      – PersonEntity:
          Name:
            NameFull: Dejardin D
      – PersonEntity:
          Name:
            NameFull: Ardeshir C
      – PersonEntity:
          Name:
            NameFull: Martin N
      – PersonEntity:
          Name:
            NameFull: Boetsch C
      – PersonEntity:
          Name:
            NameFull: Charo J
      – PersonEntity:
          Name:
            NameFull: Teichgräber V
      – PersonEntity:
          Name:
            NameFull: Kraxner A
      – PersonEntity:
          Name:
            NameFull: Keshelava N
      – PersonEntity:
          Name:
            NameFull: Bechter O
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2025 Feb 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2767-9764
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Cancer research communications
              Type: main
ResultId 1